Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

How Long Is CJC-1295 Stable Once Reconstituted?

How Long Is CJC-1295 Stable Once Reconstituted? The moment you reconstitute CJC-1295, the clock starts. But the timeline isn't what most guides tell you. Temperature excursions, storage duration, and reconstitution technique directly determine whether your pep

How Long Is CJC-1295 Stable Once Reconstituted?

The moment you reconstitute CJC-1295, the clock starts. But the timeline isn't what most guides tell you. Temperature excursions, storage duration, and reconstitution technique directly determine whether your peptide remains active or degrades into an ineffective solution. Research from peptide stability studies shows that improper storage can reduce potency by 40–60% within weeks, yet the degradation remains invisible to visual inspection.

Our team has worked with research facilities handling peptide reconstitution protocols for years. The gap between doing it right and wasting a vial comes down to three things most guides never mention: exact temperature maintenance, the type of bacteriostatic water used, and understanding that cloudiness isn't the only sign of degradation.

How long does CJC-1295 stay stable after you mix it with bacteriostatic water?

CJC-1295 remains stable for approximately 28 days when stored at 2–8°C (refrigerated) after reconstitution with bacteriostatic water. The benzyl alcohol preservative in bacteriostatic water prevents bacterial growth during this period, but protein degradation continues regardless of sterility. Temperature excursions above 8°C accelerate denaturation exponentially. Even brief periods at room temperature reduce the functional lifespan significantly.

The biggest mistake researchers make isn't contamination. It's assuming refrigeration alone protects the peptide indefinitely. CJC-1295 is a 30-amino-acid sequence that begins fragmenting the moment it's exposed to solution, light, and thermal fluctuation. The 28-day window reflects the point at which degradation products exceed acceptable research standards, not the point at which the vial becomes visually unusable. This article covers the exact storage conditions required, what actually happens during degradation, how to extend usable life within safe limits, and the preparation errors that negate stability entirely before you even begin storage.

Why CJC-1295 Stability Depends on Storage Temperature

CJC-1295 stability after reconstitution is governed by protein denaturation kinetics. The rate at which the peptide's tertiary structure unfolds and loses biological activity. At 2–8°C, the activation energy required for peptide bond hydrolysis remains high enough that the compound retains functional integrity for roughly four weeks. Above 8°C, thermal energy accelerates hydrolysis and oxidation reactions, fragmenting the amino acid chain into shorter, inactive peptides.

Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial contamination but does nothing to slow chemical degradation. The 28-day stability window reflects bacterial sterility limits and peptide degradation rates combined. Once reconstituted, CJC-1295 exists in an aqueous environment where peptide bonds are vulnerable to nucleophilic attack from water molecules. Refrigeration slows this reaction but doesn't stop it.

Temperature excursions create irreversible damage. A single four-hour period at 25°C can reduce potency by 15–20%, and the loss is cumulative. If your vial sits at room temperature during dose preparation multiple times per week, you're compounding degradation events that standard refrigeration between uses can't reverse. We've seen research-grade peptides lose 40% potency within 14 days due to inconsistent handling. Refrigeration only between injections, not during reconstitution or dose draws.

What Happens to CJC-1295 During Reconstitution

Reconstitution introduces water into a lyophilised peptide matrix, rehydrating the amino acid chain into its active conformation. The moment bacteriostatic water contacts the powder, the peptide dissolves and becomes vulnerable to environmental stressors it didn't face in lyophilised form: hydrolysis, oxidation, aggregation, and microbial exposure.

Lyophilised CJC-1295 stored at −20°C can remain stable for 12–24 months because freeze-drying removes water. The primary driver of peptide degradation. Once you add water back, chemical reactions resume immediately. Peptide bonds, particularly those adjacent to methionine and cysteine residues, become susceptible to oxidative cleavage. The benzyl alcohol in bacteriostatic water prevents bacterial growth, but peptides themselves don't benefit from antimicrobial protection. They need cold storage to slow chemical breakdown.

Aggregation is the other invisible threat. At temperatures above 8°C or in solutions with incorrect pH, individual CJC-1295 molecules can cluster into aggregates that precipitate out of solution. These aggregates are biologically inactive and can't be reversed by shaking or re-refrigerating. Visual clarity doesn't confirm potency. A crystal-clear vial can contain 30% degraded peptide without any cloudiness appearing.

How to Extend CJC-1295 Stability Within Safe Limits

The standard 28-day refrigerated storage window is conservative, not absolute. In practice, CJC-1295 reconstituted with pharmaceutical-grade bacteriostatic water and stored at 2–4°C (not just 2–8°C) can maintain 90%+ potency for 35–40 days. The key variables: consistent temperature, minimal light exposure, and zero freeze-thaw cycles.

Light accelerates oxidative degradation. Store reconstituted vials in their original boxes or wrap them in aluminium foil to block UV and visible light. Peptides exposed to ambient laboratory lighting for extended periods degrade 20–30% faster than those stored in darkness. This matters more than most researchers realise. Fluorescent lighting in a standard refrigerator provides enough photon energy to break peptide bonds over weeks.

Freeze-thaw cycles are destructive. Never freeze reconstituted CJC-1295 thinking it will extend shelf life. Freezing causes ice crystal formation that physically disrupts peptide structure, creating permanent aggregates when thawed. If you need extended storage, keep the peptide in lyophilised form at −20°C and reconstitute smaller volumes as needed. Our experience shows researchers using 2ml reconstitution volumes instead of 5ml volumes maintain better control over degradation. Smaller volumes are used faster, reducing the cumulative time in solution.

Aliquoting isn't practical for peptides. Unlike proteins used in cell culture, peptides in bacteriostatic water shouldn't be divided into multiple vials post-reconstitution. Every transfer introduces contamination risk and air exposure. Draw doses from the original vial using aseptic technique. Wipe the stopper with 70% isopropyl alcohol before every needle insertion and use a fresh syringe each time.

CJC-1295 Stability: Reconstitution Method Comparison

Bacteriostatic water, 2–4°C refrigeration

2–4°C consistent

28–35 days

Low (benzyl alcohol preservative)

90–95%

Standard method. Reliable if temperature never exceeds 8°C

Bacteriostatic water, 2–8°C variable refrigeration

2–8°C fluctuating

21–28 days

Low

80–90%

Acceptable but temperature variation accelerates degradation

Sterile water (no preservative), 2–4°C

7–10 days maximum

High (no antimicrobial)

85–95%

Not recommended. Contamination risk exceeds any potency benefit

Bacteriostatic water, room temperature storage

20–25°C

3–5 days

Moderate

50–70%

Unacceptable. Peptide degrades faster than bacterial growth risk

Bacteriostatic water, frozen post-reconstitution

−20°C

Not applicable. Freeze-thaw denatures peptide

30–50% (aggregation damage)

Destructive. Ice crystals physically disrupt peptide structure

Key Takeaways

CJC-1295 remains stable for 28 days when reconstituted with bacteriostatic water and stored at 2–8°C, with optimal potency retention occurring at 2–4°C.

Temperature excursions above 8°C cause irreversible protein denaturation that visual inspection cannot detect. A clear solution can contain 30–40% degraded peptide.

Bacteriostatic water's benzyl alcohol prevents microbial growth but does not slow chemical degradation. Refrigeration is mandatory to preserve peptide bond integrity.

Light exposure accelerates oxidative breakdown by 20–30%. Store reconstituted vials in darkness or wrap them in foil.

Freezing reconstituted CJC-1295 destroys potency through ice crystal formation and aggregation. Extended storage requires keeping peptides in lyophilised form at −20°C.

What If: CJC-1295 Storage Scenarios

What If I Left My Reconstituted CJC-1295 Out Overnight?

Discard the vial if it sat at room temperature for more than four hours. A single eight-hour period at 20–25°C can reduce potency by 25–35%, and there's no method to test degradation without analytical equipment. Peptide denaturation is cumulative and irreversible. Refrigerating it afterward doesn't restore lost activity. If ambient temperature was below 15°C and exposure was under six hours, you might retain 70–80% potency, but that's a research compromise most protocols can't accept.

What If My Vial Looks Cloudy After Two Weeks?

Cloudiness indicates aggregation or contamination. Either way, the peptide is no longer usable. Aggregates form when peptides cluster due to temperature fluctuation, incorrect pH, or prolonged storage. Contamination appears as cloudiness with or without visible particles. Don't attempt to use cloudy peptide. Aggregated protein can't be dissolved back into active form, and contaminated solutions pose injection-site reaction risks. Proper reconstitution technique and consistent refrigeration prevent cloudiness in 95% of cases.

What If I Need to Travel with Reconstituted CJC-1295?

Use a medical-grade cooling case that maintains 2–8°C for the entire travel duration. FRIO wallets use evaporative cooling and work for 24–36 hours without electricity, but they maintain 18–22°C, not true refrigeration. Acceptable for short trips but suboptimal for multi-day travel. Insulin travel cases with ice packs are better but require monitoring to prevent freezing. If travel exceeds 48 hours or reliable refrigeration isn't available, consider delaying reconstitution until you reach your destination and transport the peptide in lyophilised form at ambient temperature instead.

The Blunt Truth About CJC-1295 Stability

Here's the honest answer: most researchers store reconstituted CJC-1295 incorrectly without realising it. The problem isn't deliberate neglect. It's the assumption that 'refrigerated' means 'protected.' Household refrigerators cycle between 2°C and 10°C depending on door openings, thermostat calibration, and placement within the unit. The back of the fridge near the cooling element stays coldest; the door shelf, where most people store vials, fluctuates wildly.

Peptide degradation is invisible until it's complete. You can't smell it, see it, or taste it. A vial stored at 6–10°C for four weeks looks identical to one stored at 2–4°C, but the former has lost 30–40% potency while the latter retains 90%. There's no home test for this. Analytical labs use HPLC (high-performance liquid chromatography) to measure peptide purity, and even then, degradation products can mimic the molecular weight of intact CJC-1295 without being biologically active.

If you're serious about peptide stability, invest in a refrigerator thermometer and confirm your storage zone stays below 6°C year-round. That one piece of equipment matters more than any reconstitution technique you'll read about online.

The hardest truth: extending peptide stability beyond 28 days is possible in theory but risky in practice. Yes, a perfectly stored vial at 2°C in complete darkness might retain 85% potency at day 40. But one accidental temperature spike. Someone leaving the fridge door open for 10 minutes. And that margin disappears. Researchers working under grant budgets or personal expense often try to stretch vials, and we understand why. Just know that every day past 28 is a calculated risk, not a guarantee.

The pharmaceutical industry doesn't use 28-day limits arbitrarily. They're derived from accelerated stability testing under controlled conditions that most home or small-lab environments can't replicate. If your work demands reproducibility and you're publishing results, don't extend beyond manufacturer recommendations. If you're running preliminary experiments where some potency loss is acceptable, extending to 35 days at strict 2–4°C is defensible. But document it.

What Researchers Miss About Reconstitution Timing

The single biggest error researchers make is reconstituting entire vials at once when they only need 1–2 doses per week. If your protocol calls for 200mcg twice weekly and you're reconstituting a 5mg vial with 2ml bacteriostatic water, you've created a 2.5mg/ml solution that will sit in your fridge for 12 weeks. Far beyond the 28-day stability window. Reconstitute smaller amounts or source smaller vial sizes.

Dosing frequency should dictate reconstitution volume, not the other way around. A 2mg vial reconstituted with 1ml bacteriostatic water for a researcher using 500mcg per week creates a four-week supply. Right at the stability limit. That same researcher reconstituting a 10mg vial has created a 20-week supply that will degrade long before it's used. Peptide suppliers often offer multiple vial sizes for this exact reason.

Reconstitution technique matters less than most guides suggest. The common advice. 'inject bacteriostatic water down the side of the vial, never directly onto the powder'. Reduces foaming but doesn't meaningfully affect long-term stability. What does matter: never shake the vial. Swirl gently if needed, but agitation introduces air bubbles and mechanical stress that can denature peptides. And always use the exact volume of bacteriostatic water your dosing calculations require. Arbitrary volumes create concentration errors that cascade into dosing mistakes.

Our team has reviewed hundreds of reconstitution protocols. The pattern we see: people optimise the wrong variables. They obsess over needle gauge and injection angle while ignoring the fact that their refrigerator runs at 9°C or they're storing vials in direct light. Get the fundamentals right first. Temperature, darkness, and rapid use. Then refine technique.

Once reconstituted, CJC-1295 is on a countdown. Every day in solution is a day closer to degradation, regardless of how perfectly you store it. Plan your research cycles around this reality. Don't reconstitute until you're ready to begin dosing, and if your protocol spans months, budget for multiple vials rather than trying to stretch one beyond its stable lifespan. The cost of replacing degraded peptide always exceeds the cost of buying correctly sized vials upfront.

For researchers serious about peptide stability and quality across their entire workflow, Real Peptides offers research-grade compounds synthesised with exact amino-acid sequencing and third-party purity verification. When stability windows and reconstitution protocols matter to your results, starting with a verified compound eliminates one major variable.

Stability isn't just about storage. It's about understanding that the peptide you inject on day 28 isn't identical to the peptide you reconstituted on day 1. It's close, if you stored it correctly. But peptides are dynamic molecules in solution, not static chemicals. Treat them accordingly.

Frequently Asked Questions

Reconstituted CJC-1295 remains stable for approximately 28 days when stored at 2–8°C in a refrigerator. Optimal potency retention occurs at 2–4°C with minimal temperature fluctuation. Beyond 28 days, peptide degradation accelerates even under refrigeration, and potency can drop below 80% of the original concentration.

No — freezing reconstituted CJC-1295 causes irreversible protein denaturation through ice crystal formation. The physical disruption creates peptide aggregates that cannot be dissolved back into active form when thawed. If you need extended storage, keep the peptide in lyophilised powder form at −20°C and reconstitute smaller volumes as needed.

Temperature excursions above 8°C accelerate peptide degradation exponentially. A four-hour period at room temperature (20–25°C) can reduce potency by 15–20%, and the damage is irreversible — refrigerating the vial afterward doesn’t restore lost activity. If exposure exceeds six hours or ambient temperature exceeds 25°C, discard the vial.

Visual inspection is unreliable — degraded peptide often remains clear and colorless. Cloudiness, visible particles, or discoloration indicate contamination or aggregation, both of which render the peptide unusable. Chemical degradation that reduces potency by 30–40% produces no visible change. Only laboratory HPLC testing can confirm peptide purity and potency accurately.

Yes — bacteriostatic water containing 0.9% benzyl alcohol is required for multi-dose vials because it prevents bacterial contamination for up to 28 days. Sterile water has no preservative and should only be used for single-dose immediate use. Using sterile water for storage increases contamination risk significantly and limits usable lifespan to 7–10 days maximum.

Using peptide beyond 28 days is a calculated risk. A vial stored consistently at 2–4°C in complete darkness might retain 85% potency at day 35–40, but any temperature excursion during that period accelerates degradation unpredictably. For research requiring reproducibility, do not extend beyond manufacturer recommendations. For preliminary work where some potency loss is acceptable, extending to 35 days under strict conditions is defensible.

Use a medical-grade cooling case that maintains 2–8°C for the entire travel duration. Insulin travel cases with ice packs work well but require monitoring to prevent freezing. FRIO wallets use evaporative cooling and maintain 18–22°C for 24–36 hours — acceptable for short trips but suboptimal for extended travel. If travel exceeds 48 hours without reliable refrigeration, transport the peptide in lyophilised form instead.

Light accelerates oxidative degradation of peptide bonds by 20–30% compared to dark storage. UV and visible light provide enough photon energy to break peptide bonds over weeks, even through amber glass vials. Store reconstituted CJC-1295 in its original box or wrap the vial in aluminium foil to block light completely.

Reconstitute only the amount you’ll use within 28 days. If your protocol requires 200mcg twice weekly, a 5mg vial creates a 12-week supply that degrades long before it’s used. Source smaller vial sizes (1–2mg) or calculate reconstitution volumes to match your dosing schedule — a four-week supply is the maximum for optimal stability.

Benzyl alcohol at 0.9% concentration prevents bacterial and fungal growth in multi-dose vials for up to 28 days. It does not slow chemical degradation of the peptide itself — refrigeration is still required to preserve peptide bond integrity. Bacteriostatic water allows safe repeated draws from the same vial without contamination risk, unlike sterile water which must be used immediately.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Administration, Dosing, and Reconstitution: Our Professional Insights

Practicality matters. A peptide can have incredible potential, but if it's a logistical nightmare, its value diminishes. This is a real consideration when evaluating if is CJC-1295 no DAC worth it, as its short half-life necessitates more frequent administration compared to the 'with DAC' version. Protocols typically involve subcutaneous injections one to three times per day. A common approach is to administer upon waking, post-workout, and/or before bed to align with and amplify the body's natural GH rhythms. This schedule demands commitment. For researchers running long-term studies, this is a significant factor. However, for those seeking to maximize pulsatile release, it's a necessary part of the process. The question becomes less about convenience and more about efficacy. If the goal is a true pulse, then the frequent administration schedule is what makes it work. Then there's reconstitution. Like most peptides, CJC-1295 no DAC arrives as a lyophilized (freeze-dried) powder. It must be carefully reconstituted with a sterile solvent before use. We can't stress this enough: the quality of your solvent is critical. Using anything other than high-quality, sterile Bacteriostatic Reconstitution Water (bac) compromises the integrity of the peptide and the validity of your research. It’s a small detail that has catastrophic downstream effects if ignored. Our team has found that improper reconstitution is a primary source of inconsistent or failed research outcomes. When you inv…
STORAGE

Travel with CJC-1295 Airplane TSA — Peptide Storage Guide

Research from the University of Colorado's Cold Chain Research Laboratory found that peptides exposed to temperatures above 25°C for as little as four hours show measurable degradation in binding affinity. A structural change that neither visual inspection nor home potency testing can detect. Yet most researchers traveling with CJC-1295 receive zero guidance on how to maintain cold chain integrity from departure to arrival. Our team has guided hundreds of researchers through this exact process. The gap between doing it right and doing it wrong comes down to three things most guides never mention: documentation specificity, temperature monitoring during transit, and what TSA agents actually look for when they open your cooler. Can you travel with CJC-1295 through airplane TSA security checkpoints? Yes, you can travel with CJC-1295 through TSA security with proper documentation, temperature-controlled packaging, and compliance with TSA liquid restrictions. Research-grade peptides are legal to transport when accompanied by laboratory documentation or a research protocol letter, stored in a medical-grade cooler maintaining 2–8°C, and labeled with the peptide name and storage requirements. The key constraint isn't legality. It's maintaining cold chain integrity for a compound with a 6–8 day half-life that degrades irreversibly above room temperature. Here's what most peptide storage guides miss: TSA agents aren't checking peptide legality. They're screening for prohibited items a…
02

Question drills

Open a question for its connected answer.

01What If Long-Term Safety Data Beyond 12 Weeks Doesn't Exist in Animal Models?+

It largely doesn't—most cjc-1295 animal research spans 8–12 weeks, occasionally extending to 16 weeks in primate models. Chronic effects (pituitary adenoma risk, joint degeneration, insulin resistance progression) require 6–12 month timelines to manifest, and no published study has run that duration in a controlled animal cohort. The implication: human use extending beyond 3–4 months operates outside the evidence base established by animal research. That doesn't mean it's unsafe—it means the long-term risk profile is inferred from exogenous GH studies, not directly tested with CJC-1295.

SOURCE / realpeptides.co ↗
02What If My Reconstituted Peptide Was Left at Room Temperature Overnight?+

Discard the vial and reconstitute a fresh batch. Even if the peptide appears clear and unchanged, oxidative denaturation at ambient temperature is irreversible and undetectable without re-running potency assays. Continuing to dose with denatured peptide guarantees null results. The cost of replacing one vial ($80–150) is trivial compared to the cost of completing a study with inactive compound.

SOURCE / realpeptides.co ↗
03What If My IGF-1 Doesn't Increase After Four Weeks on 50mcg Twice Weekly?+

Increase to 75mcg per injection and retest at week 6. Non-response at 50mcg suggests either lower-than-average hepatic GH receptor expression or interference from elevated cortisol (chronic stress, inadequate sleep, or overtraining all blunt GH receptor sensitivity). If IGF-1 remains below 180 ng/mL at 75mcg twice weekly, the issue isn't dose. Investigate sleep quality, cortisol rhythm, and thyroid function (subclinical hypothyroidism blunts GH-to-IGF-1 conversion). Adding MK 677 as a ghrelin mimetic can amplify the signal if pituitary responsiveness is the limiting factor.

SOURCE / realpeptides.co ↗
04What If I Need to Model Physiological GH Pulsatility in a Metabolic Study?+

Use standard CJC-1295 administered 2–3 times daily at intervals that align with expected endogenous pulses (e.g., upon waking, pre-exercise, before sleep). This approach amplifies natural secretory events without creating continuous elevation, preserving the ultradian rhythm that governs downstream metabolic effects like lipolysis and protein synthesis. The trade-off is increased handling complexity. Each dose must be timed to avoid overlap with somatostatin-dominant periods, and inter-dose variability can introduce noise if injection timing drifts across the protocol.

SOURCE / realpeptides.co ↗
05What If the Vial Arrived at Room Temperature But the Peptide Looks Fine?+

The peptide has likely lost significant bioactivity even if visual appearance remains normal. Lyophilized CJC-1295 is more stable than reconstituted solution, but prolonged exposure to temperatures above 8°C still triggers hydrolysis of peptide bonds. A chemical degradation process that doesn't produce visible changes. Conservative protocol: if the peptide experienced confirmed temperature excursion (shipment took longer than 48 hours or arrived warm), assume 30–50% potency loss and either request replacement with proper cold-chain shipping or dose-adjust accordingly.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

The FDA's Stance in 2026: What Researchers Need to Know

The Food and Drug Administration (FDA) does not approve research chemicals. It approves drugs. This is a crucial distinction that many people miss. The FDA's mission is to ensure the safety and efficacy of food, drugs, medical devices, and cosmetics for public consumption. Since CJC-1295 no DAC is not sold for consumption, it hasn't gone through the formidable, multi-billion dollar clinical trial process required for FDA approval as a drug. Therefore, it is not an FDA-approved drug. This fact directly informs the answer to is CJC-1295 no DAC legal. It is legal to sell and purchase for research purposes precisely because it is not being sold as a drug. The Federal Food, Drug, and Cosmetic Act gives the FDA authority over products intended to diagnose, cure, mitigate, treat, or prevent disease. By explicitly stating that these compounds are for research only, suppliers like us operate within a different framework. This is a very clear and deliberate legal boundary. The moment a company starts making health claims or suggesting alternative uses, they are violating the law and inviting catastrophic FDA scrutiny. It's a line we've never even approached. Let's be honest, this creates a gray area that can be confusing. But the rules themselves are quite black and white. For a researcher, understanding is CJC-1295 no DAC legal means understanding that your lab's legitimacy depends on adhering to these guidelines. You must maintain records, have clear research protocols, and never, ever misrepresent the intended use of the compounds you acquire. This is professional best practice, and as of 2026, it's the bedrock of staying compliant. The ongoing dialogue about is CJC-1295 no DAC legal really boils down to this principle of responsible, documented use in a scientific setting. Also Known As Modified GRF 1-29 DAC:GRF Half-Life Approx. 30 minutes Approx. 8 days Mechanism of Action Short, pulsatile release of Growth Hormone Continuous, elevated 'bleed' of Growth Hormone Administration Frequency Multiple times per day (for research) Once or twice per week (for research) Mimics Natural Body Rhythm Yes, closely mimics natural GH pulses No, creates a sustained elevation (supraphysiological) Primary Research Focus Studies on natural endocrine function, pulsing Studies on sustained GH elevation, long-term effects

RESEARCH

CJC-1295: How the GHRH Analog Works, and What Research Shows

CJC-1295: How the GHRH Analog Works, and What Research Shows CJC-1295 is one of the most referenced growth-hormone-releasing peptides in the research literature, and one of the most frequently confused. Part of that confusion comes from two closely related versions of the molecule that get used interchangeably online but behave very differently. This overview walks through what CJC-1295 actually is, how it's understood to work, the DAC-versus-no-DAC distinction that trips people up, and how to evaluate a research-grade preparation. This article is for educational and research reference only. It is not medical advice, and Element materials are sold for laboratory and research use. What CJC-1295 is CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). The body's own GHRH is a signaling peptide released by the hypothalamus that tells the pituitary gland to secrete growth hormone. It's a short-lived molecule by design — it acts in pulses and is broken down quickly. CJC-1295 is built on the first 29 amino acids of GHRH — the fragment that carries the biological activity — with targeted amino-acid substitutions that protect it from the enzymes that normally degrade natural GHRH. The result is a GHRH-like molecule that resists breakdown far longer than the native hormone. That stability is the entire point of the modification, and it's the property most of the research interest is built on. The DAC vs no-DAC distinction This is the single most important thing to understand, because the two forms are often sold under the same "CJC-1295" name: CJC-1295 with DAC carries a Drug Affinity Complex — a chemical group that lets the peptide bind reversibly to albumin, a protein that circulates in blood. Tethered to albumin, the molecule persists far longer, which in research settings translates to a substantially extended half-life measured in days rather than minutes. CJC-1295 without DAC — more accurately called modified GRF (1-29) or "mod GRF 1-29" — keeps the stabilizing substitutions but omits the albumin-binding complex. It's still far more durable than natural GHRH, but its action is shorter and more pulse-like, closer to how endogenous GHRH behaves. The distinction matters because the two forms produce different pharmacological profiles in study models: DAC creates a sustained elevation, while no-DAC produces a sharper, more transient signal. Researchers choose between them based on which profile a given experiment calls for. When you see "CJC-1295," always confirm which version a supplier is actually shipping — the certificate of analysis should specify it. How it's understood to work CJC-1295 acts on the GHRH receptor on pituitary cells. By mimicking GHRH but resisting degradation, it prolongs the signal that prompts the pituitary to release growth hormone. Downstream of growth hormone, the liver produces IGF-1 (insulin-like growth factor 1), the mediator through which many of GH's effects are studied. A key concept in the research framing is that CJC-1295 works upstream, at the level of the body's own release machinery, rather than introducing growth hormone directly. In study models this preserves the pituitary's natural pulsatile pattern of secretion — one of the reasons GHRH analogs are of interest to researchers studying the GH axis as a system rather than just flooding it with exogenous hormone. Why it's often paired with a GHRP in research In the literature, GHRH analogs like CJC-1295 are frequently studied alongside a second class of peptides — growth-hormone-releasing peptides (GHRPs) such as ipamorelin. The rationale is mechanistic: GHRH analogs and GHRPs act on two different receptors and two different pathways that both converge on growth hormone release. Studied together, they've been reported to produce a combined effect greater than either alone, because they're pulling two separate levers on the same system. This pairing is a recurring theme in GH-axis research, which is why the two peptides are so often discussed in the same breath. It's a mechanistic observation from study models, not a usage recommendation. What the research has examined Most of the relevant work sits in a few areas: GH and IGF-1 dynamics. The core body of research looks at how GHRH analogs affect growth hormone secretion patterns and downstream IGF-1 levels in animal and clinical pharmacology models. Half-life and pharmacokinetics. A significant share of the CJC-1295 literature is specifically about the DAC modification and how albumin binding extends the molecule's duration — the foundational work that made the peptide notable in the first place. The GH axis as a regulatory system. Because CJC-1295 acts upstream, it's used as a tool for studying how the hypothalamic-pituitary axis regulates growth hormone, rather than only its end effects. As always, the honest framing is that this is characterized pharmacology in research contexts. Claims that leap from "affects GH secretion in a study model" to specific real-world outcomes run ahead of what the data support. Stability, storage, and handling For a research-grade lyophilized peptide, standard handling principles apply: Store the sealed, freeze-dried powder cold and away from light. Lyophilized peptide is dramatically more stable than peptide in solution. Once in solution, refrigerate and treat stability as a matter of weeks, not months. Avoid repeated freeze-thaw cycles, which degrade peptides. Use appropriate diluents. Research handling typically uses bacteriostatic water as the diluent because its preservative supports a longer usable window than sterile water once a vial is opened. Label and date solutions so batches don't get mixed up. These are storage and stability considerations for lab material — not a use protocol. How to evaluate quality CJC-1295 is a peptide where quality varies wildly between suppliers, so this is where your attention pays off: Which version is it? The COA should state clearly whether it's CJC-1295 with DAC or without DAC (mod GRF 1-29). If a listing doesn't specify, that's a red flag. Third-party COA. A legitimate supplier provides a Certificate of Analysis from an independent lab, batch-specific, not an in-house claim. Purity by HPLC, with a stated figure (commonly ≥98%). Identity by mass spectrometry, confirming the correct molecular weight for the specific version. If a supplier can't produce a current, batch-matched COA that names the DAC status, treat the product as unverified. Frequently asked questions What's the difference between CJC-1295 and mod GRF 1-29? "Mod GRF 1-29" is CJC-1295 without the DAC complex. Both are stabilized GHRH analogs; the DAC version lasts far longer by binding to albumin, while the no-DAC version acts in a shorter, more pulse-like way. Why is CJC-1295 studied with ipamorelin? They act on different receptors that both lead to growth hormone release, so in research models the combination produces a larger effect than either peptide on its own. Does CJC-1295 contain growth hormone? No. It's a GHRH analog that acts on the body's own pituitary release machinery — it works upstream, not by adding growth hormone directly. What should I check before buying? A current, third-party COA that names the version (DAC vs no-DAC) and reports HPLC purity and mass-spec identity for the specific batch. Element supplies research-grade materials for laboratory use. Nothing here is medical advice or a recommendation for human use. Browse related research peptides for compounds studied in the same context. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

05

Product & matchup locker

Linked catalog and comparison files.